1-[(2S)-1-methoxypropan-2-yl]oxy-2,2-dimethylpropane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[(2S)-1-methoxypropan-2-yl]oxy-2,2-dimethylpropane
• 化学式: C₉H₂₀O₂
• 分子量: 160.25
• InChiKey: YIHXZJLCBMMSOL-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG
  申请人：Kamenecka Theodore Mark

  公开号：US20140288090A1

  公开（公告）日：2014-09-25

  The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  本发明提供了分子实体，其与PPARG（PPARγ）具有高亲和力，抑制cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用。本发明的化合物可用于治疗患有PPARG发挥作用的疾病，例如糖尿病或肥胖症的患者。还提供了制备化合物的方法，评估本发明化合物作为非激动性PPARG结合化合物的生物测定方法以及制药组合物。
• N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG
  申请人：RIPKA Amy S.

  公开号：US20150141464A1

  公开（公告）日：2015-05-21

  The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5 -mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  本发明提供了与PPARG（PPARγ）高亲和力结合，抑制cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用的分子实体。本发明的化合物可用于治疗PPARG在糖尿病或肥胖症患者中发挥作用的情况。本发明还提供了制备该化合物的方法，评估该化合物作为非激动性PPARG结合化合物的生物测定方法以及制药组合物。
• N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG
  申请人：Kamenecka Theodore Mark

  公开号：US20140249196A1

  公开（公告）日：2014-09-04

  The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  本发明提供了与PPARG（PPARγ）高亲和力结合、抑制cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用的分子实体。本发明的化合物可用于治疗PPARG在糖尿病或肥胖等病患中发挥作用的情况。本发明还提供了化合物的制备方法、评估本发明的化合物作为非激动性PPARG结合化合物的生物测定方法和制药组合物。
• US9309227B2
  申请人：——

  公开号：US9309227B2

  公开（公告）日：2016-04-12